Insider · CIK 0001793412
Kamran Alam
Files at TSHA (Taysha Gene Therapies, Inc.). First filing Aug 22, 2025, latest Feb 6, 2026.
In brief
Kamran Alam files SEC Form 4 as CFO at TSHA (Taysha Gene Therapies, Inc.). Since Aug 22, 2025, Kamran Alam has reported 0 open-market buys worth $0 and 3 open-market sells worth $648k, the latest filed on Feb 6, 2026.
A track record needs three past buys with six months of prices behind them; Kamran Alam has 0, so none is measured yet.
The newest scored trade: sold $7,481 of TSHA on Feb 4, 2026, filed Feb 6, 2026, scored 37 (weak). In the last 12 months: 0 buys worth $0 and 2 sells worth $493k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
TSHA: Taysha Gene Therapies, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 37Weak | Taysha Gene Therapies, Inc. | $7,481 1,655 shares | -0% | +302% from low-23% from high | |
| 55Moderate | Taysha Gene Therapies, Inc. | $485k 102,817 shares | -7% | +312% from low-21% from high | |
| 41Moderate | Taysha Gene Therapies, Inc. | $155k 54,491 shares | -4% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Feb 4, 2026 | TSHA TAYSHA GENE THERAPIES, INC. | 1,655 0.00% of outstanding | $7,812 | Feb 4, 2026 | $485k |
| Jan 23, 2026 | TSHA TAYSHA GENE THERAPIES, INC. | 100,846 0.04% of outstanding | $513k | Jan 23, 2026 | none |
| Aug 21, 2025 | TSHA TAYSHA GENE THERAPIES, INC. | 54,491 0.02% of outstanding | $156k | Aug 21, 2025 | none |
Transactions
Every row this insider has filed, 11 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 4, 2026 | TSHA Taysha Gene Therapies, Inc. | SOpen-market sale Common Stock | -1,655 | $4.52 | $7,481 | 1,442,131 | Feb 6, 2026 |
| Jan 23, 2026 | TSHA Taysha Gene Therapies, Inc. | SOpen-market sale Common Stock | -78,968 | $4.75 | $375k | 1,467,635 | Jan 27, 2026 |
| Jan 26, 2026 | TSHA Taysha Gene Therapies, Inc. | SOpen-market sale Common Stock | -23,849 | $4.61 | $110k | 1,443,786 | Jan 27, 2026 |
| Jan 12, 2026 | TSHA Taysha Gene Therapies, Inc. | AGrant or award Common Stock | +359,000 | $0.00 | $0 | 1,546,603 | Jan 14, 2026 |
| Jan 12, 2026 | TSHA Taysha Gene Therapies, Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +231,000 | $0.00 | $0 | 231,000 | Jan 14, 2026 |
| Aug 21, 2025 | TSHA Taysha Gene Therapies, Inc. | SOpen-market sale Common Stock | -54,491 | $2.85 | $155k | 1,187,603 | Aug 22, 2025 |
| May 31, 2023 | TSHA Taysha Gene Therapies, Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +12,462 | $0.00 | $0 | 12,462 | Apr 10, 2025 |
| Mar 11, 2025 | TSHA Taysha Gene Therapies, Inc. | FTax withholding Common Stock | -29,843 | $1.69 | $50k | 1,242,094 | Mar 13, 2025 |
| Jan 2, 2025 | TSHA Taysha Gene Therapies, Inc. | AGrant or award Common Stock | +431,000 | $0.00 | $0 | 1,271,937 | Jan 3, 2025 |
| Jan 2, 2025 | TSHA Taysha Gene Therapies, Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +431,000 | $0.00 | $0 | 431,000 | Jan 3, 2025 |
| Dec 14, 2023 | TSHA Taysha Gene Therapies, Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +187,582 | $0.00 | $0 | 187,582 | Dec 18, 2023 |
Questions about Kamran Alam
Answered from the filings on this page, as of the latest one.
Is Kamran Alam buying or selling?
In the last 12 months Kamran Alam reported 0 open-market buys worth $0 and 2 open-market sells worth $493k on SEC Form 4; the latest was sold $7,481 of TSHA on Feb 4, 2026. Grants, option exercises and tax withholding are not counted.
How did Kamran Alam's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Kamran Alam has 0.
Where does Kamran Alam file Form 4?
Kamran Alam has filed Form 4 at TSHA (Taysha Gene Therapies, Inc.) as Chief Financial Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.